For the past few months, a good number of COVID-19 vaccines got their approval. The approval is for the general or the emergency usage in the regions of the Middle East and North Africa. Also, the data of the Vaccine Centre at the London School of Hygiene & Tropical Medicine and the various regional media statements of the government show the round-up of the COVID vaccines.
The most common ones lack any kind of particular order. The most common ones are by- Sinopharm, Sinovac, Pfizer-BioNTech, Sputnik V, Oxford-AstraZeneca, and Moderna. However, the whole virus vaccine of Sinopharm has 56128 numbers of total registered trials. The data efficiency is 79%. It comes with the refrigeration requirement for storage. Up to 1 billion doses are for the manufacturer projection. This one also got approval for full or emergency uses in China.
Sinopham, on the other hand, comes with 52864 registered trials. It is best stored with refrigeration and gets approval for only limited use in China and United Arab Emirates- as under the MENA region. Sinovac went through 32738 registered trials. As the media report says, it also has the capabilities of 600 million doses per year. The approval status comes with limited use in China and Egypt.
The RNA or mRNA vaccines have gone through 45838 registered trials. The storage requirement is also ultra-cold. As per the manufacturer projection, it will have 1.3 billion doses per year. WHO granted it the full or emergency in numerous countries. Moderna has passed 33720 registered trials. However, the manufacturer projection is up to 1 billion doses per year. The approval is for the USA, Canada, EU, and the UK.
Oxford-AstraZeneca has approval in the UK, India, Argentina, Dominican Republic and El Salvador, Egypt, and Libya. Sputnik V, on the other hand, for approval in Russia, Belarus, Serbia, Argentia, Algeria, Palestine, and Egypt for the MENA regions. The protein subunits are not yet approved for use. However also the approval of the vaccines does not come with the note of reliability of efficiency yet.